VENUS REMEDIES LIMITED (VENUSREM) financials

VENUS REMEDIES LIMITED (VENUSREM) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1989, Venus RemediesLtd is a research-based pharmaceutical company focused on complex injectable formulations across critical care, oncology, anti-infectives and specialty therapies. It operates across 100+ countries, with a product basket of 195+, 1,100+ marketing authorisations and 700+ dossiersfiled.{# {# https://www.bseindia.com/xml-data/corpfiling/AttachHis/29971821-bfab-4659…

Market Cap: ₹2,206Cr.
Current Price: ₹1,651
Stock P/E: 19.5
ROE: 14.4%
ROCE: 19.3%
Book Value: ₹516
Dividend Yield: 0.61%
52W High / Low: ₹2,044/432

In Jun 2026, VENUS REMEDIES LIMITED (VENUSREM) reported sales ₹179 Cr and net profit ₹26 Cr.

Annual TTM: sales ₹810 Cr, net profit ₹113 Cr.

Shareholding: Promoters 41.76% (Sep 2026), FIIs 3.14% (Sep 2026), DIIs 0.74% (Sep 2026), Public 54.37% (Sep 2026), No. of Shareholders 22,968% (Sep 2026).

VENUSREM quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	170	172	197	137	193	180	259	179
Expenses	157	150	171	119	163	143	200	142
Operating Profit	13	23	25	18	30	37	59	37
OPM %	8%	13%	13%	13%	15%	20%	23%	20%
Other Income	8	12	4	3	2	2	5	3
Interest	0	0	0	0	0	0	0	0
Depreciation	6	5	4	6	6	6	7	7
Profit before tax	15	29	25	15	26	33	58	33
Tax %	37%	18%	40%	20%	25%	24%	25%	22%
Net Profit	9	24	15	12	19	25	43	26
EPS in Rs	6.93	18.01	11.06	8.75	14.39	18.64	32.51	19.10
Raw PDF	—	—	—	—	—	—	—	—

VENUSREM profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	316	511	574	534	570	636	765	810
Expenses	273	464	505	473	509	561	621	648
Operating Profit	43	47	69	62	61	75	144	163
OPM %	14%	9%	12%	12%	11%	12%	19%	20%
Other Income	-5	41	8	10	11	26	11	11
Interest	13	13	0	0	0	0	0	0
Depreciation	31	34	33	31	26	22	25	25
Profit before tax	-6	41	45	40	47	79	131	149
Tax %	31%	-32%	-10%	28%	35%	34%	24%	—
Net Profit	-8	54	49	29	30	53	99	113
EPS in Rs	-6.67	43.97	36.65	21.67	22.82	39.32	74.29	84.64
Dividend Payout %	0%	0%	0%	0%	0%	0%	13%	—

VENUSREM balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	12	12	12	13	13	13	13	13
Reserves	329	320	388	436	465	495	576	676
Borrowings	294	216	48	39	39	39	0	12
Other Liabilities	97	96	99	91	92	94	124	174
Total Liabilities	732	644	547	579	609	641	713	876
Fixed Assets	347	271	244	225	200	203	214	215
CWIP	65	25	25	25	26	21	26	51
Investments	0	0	0	0	20	19	84	238
Other Assets	320	348	277	329	363	398	388	372
Total Assets	732	644	547	579	609	641	713	876

VENUSREM cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	44	78	132	41	28	35	83	151
Cash from Investing Activity	-11	-5	56	-17	-51	-7	-76	-182
Cash from Financing Activity	-35	-72	-162	-9	0	0	0	-1
Net Cash Flow	-2	1	26	15	-23	28	7	-32
Free Cash Flow	34	70	132	27	20	23	65	114
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	127%	181%	282%	60%	46%	84%	131%	129%

VENUSREM shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%	41.76%
FIIs	1.11%	1.34%	2.25%	1.86%	2.25%	2.80%	2.92%	3.14%
DIIs	0.00%	0.00%	0.11%	0.75%	1.03%	1.20%	0.89%	0.74%
Public	57.13%	56.90%	55.89%	55.62%	54.95%	54.24%	54.44%	54.37%
No. of Shareholders	19,771	19,982	19,307	17,725	18,606	18,403	21,905	22,968

VENUSREM key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	38	34	12	19	58	57	57	56
Inventory Days	283	282	130	121	123	122	98	122
Days Payable	67	70	74	48	53	54	67	104
Cash Conversion Cycle	254	246	67	93	129	126	88	73
Working Capital Days	-3	77	68	84	118	129	97	70
ROCE %	1%	3%	6%	10%	8%	9%	12%	19%

VENUSREMUpdated 18 Oct 2026, 5:34

Venus Remedies Limited

VENUSREMUpdated 18 Oct 2026, 5:34

Market Cap

₹2,206Cr.

Current Price

₹1,651

High / Low

₹2,044/432

Stock P/E

19.5

ROE14.4%

ROCE19.3%

Book Value₹516

Face Value₹10.0

Dividend Yield0.61%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	99	85	2	7	8	47	4	3.25
Sep 2023	170	157	3	6	10	45	5	4.08
Dec 2023	131	118	2	6	9	10	8	6.13
Mar 2024	175	154	4	6	19	36	13	9.36
Jun 2024	106	92	2	6	10	56	4	3.33
Sep 2024	170	157	8	6	15	37	9	6.93
Dec 2024	172	150	12	5	29	18	24	18.01
Mar 2025	197	171	4	4	25	40	15	11.06
Jun 2025	137	119	3	6	15	20	12	8.75
Sep 2025	193	163	2	6	26	25	19	14.39
Dec 2025	180	143	2	6	33	24	25	18.64
Mar 2026	259	200	5	7	58	25	43	32.51
Jun 2026	179	142	3	7	33	22	26	19.1

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	443	41	356	1	45	2	-123	5	3.98
Mar 2016	392	37	312	1	40	3	60	1	1.05
Mar 2017	375	34	328	1	39	-25	-18	-20	-16.4
Mar 2018	355	35	312	1	33	-23	13	-27	-21.54
Mar 2019	299	25	265	-4	33	-28	-4	-27	-21.97
Mar 2020	316	13	273	-5	31	-6	31	-8	-6.67
Mar 2021	511	13	464	41	34	41	-32	54	43.97
Mar 2022	574	0	505	8	33	45	-10	49	36.65
Mar 2023	534	0	473	10	31	40	28	29	21.67
Mar 2024	570	0	509	11	26	47	35	30	22.82
Mar 2025	636	0	561	26	22	79	34	53	39.32
Mar 2026	765	0	621	11	25	131	24	99	74.29
TTM	810	0	648	11	25	149	—	113	84.64

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	41.76%
FIIs	3.14%
DIIs	0.74%
Public	54.37%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2023	41.76%	1.59%	0%	56.65%
Mar 2024	41.76%	1.48%	0%	56.76%
Jun 2024	41.76%	1.06%	0%	57.17%
Sep 2024	41.76%	1.18%	0%	57.06%
Dec 2024	41.76%	1.11%	0%	57.13%
Mar 2025	41.76%	1.34%	0%	56.9%
Jun 2025	41.76%	2.25%	0.11%	55.89%
Sep 2025	41.76%	1.86%	0.75%	55.62%
Dec 2025	41.76%	2.25%	1.03%	54.95%
Mar 2026	41.76%	2.8%	1.2%	54.24%
Jun 2026	41.76%	2.92%	0.89%	54.44%
Sep 2026	41.76%	3.14%	0.74%	54.37%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	11	455	319	60	845	426	78	29	312	845
Mar 2016	11	433	327	63	834	434	80	29	291	834
Mar 2017	12	382	308	65	767	389	66	29	283	767
Mar 2018	12	356	302	78	748	370	65	0	314	748
Mar 2019	12	329	294	97	732	347	65	0	320	732
Mar 2020	12	320	216	96	644	271	25	0	348	644
Mar 2021	12	388	48	99	547	244	25	0	277	547
Mar 2022	13	436	39	91	579	225	25	0	329	579
Mar 2023	13	465	39	92	609	200	26	20	363	609
Mar 2024	13	495	39	94	641	203	21	19	398	641
Mar 2025	13	576	0	124	713	214	26	84	388	713
Mar 2026	13	676	12	174	876	215	51	238	372	876

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	67	-67	0	-1
Mar 2016	42	3	-46	0
Mar 2017	62	-18	-44	0
Mar 2018	52	-11	-40	0
Mar 2019	44	-11	-35	-2
Mar 2020	78	-5	-72	1
Mar 2021	132	56	-162	26
Mar 2022	41	-17	-9	15
Mar 2023	28	-51	0	-23
Mar 2024	35	-7	0	28
Mar 2025	83	-76	0	7
Mar 2026	151	-182	-1	-32

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	49	50	41	45	38	34	12	19	58	57	57	56
Inventory Days	189	210	230	242	283	282	130	121	123	122	98	122
Days Payable	35	36	50	48	67	70	74	48	53	54	67	104
Cash Conversion Cycle	203	223	220	239	254	246	67	93	129	126	88	73
Working Capital Days	54	73	52	23	-3	77	68	84	118	129	97	70
ROCE %	6%	5%	1%	2%	1%	3%	6%	10%	8%	9%	12%	19%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of VENUS REMEDIES LIMITED (VENUSREM)?

The reported market capitalisation for VENUS REMEDIES LIMITED (VENUSREM) is ₹2,206Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of VENUSREM?

The current price shown for VENUS REMEDIES LIMITED (VENUSREM) on Fincrux is ₹1,651 with a 52-week high/low of ₹2,044/432.

What is the P/E ratio of VENUS REMEDIES LIMITED (VENUSREM)?

The stock P/E for VENUS REMEDIES LIMITED (VENUSREM) is 19.5 on Fincrux, with ROE at 14.4% and ROCE at 19.3%.

What were VENUSREM latest quarterly results?

For Jun 2026, VENUS REMEDIES LIMITED (VENUSREM) reported sales ₹179 Cr and net profit ₹26 Cr (figures in ₹ crore unless noted).

What are VENUSREM annual sales and net profit?

For TTM, VENUS REMEDIES LIMITED (VENUSREM) shows sales of ₹810 Cr and net profit of ₹113 Cr on the Fincrux profit & loss statement.

Who owns VENUS REMEDIES LIMITED (VENUSREM)?

Latest shareholding for VENUS REMEDIES LIMITED (VENUSREM) on Fincrux: Promoters 41.76% (Sep 2026), FIIs 3.14% (Sep 2026), DIIs 0.74% (Sep 2026), Public 54.37% (Sep 2026), No. of Shareholders 22,968% (Sep 2026).

Where can I find VENUS REMEDIES LIMITED (VENUSREM) financials?

VENUS REMEDIES LIMITED (VENUSREM) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show VENUSREM balance sheet and cash flow?

Yes. The VENUS REMEDIES LIMITED (VENUSREM) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 18 October 2026 at 5:34